Neoadjuvant Immunotherapy-From Trials to Practice

Elizabeth A Mittendorf^{1

2

3}, Sara M Tolaney^{2

3

4}

Affiliations

¹ Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Comment

Elizabeth A Mittendorf et al. JAMA Oncol. 2024.

. 2024 Oct 1;10(10):1319-1321.

doi: 10.1001/jamaoncol.2024.2924.

Elizabeth A Mittendorf^{1

2

3}, Sara M Tolaney^{2

3

4}

¹ Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

No abstract available

Comment on

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P, Martínez-Sáez O, Sánchez-Bayona R, Ferrero-Cafiero JM, Salvador F, Papakonstantinou A, Prat A, Oliveira M, Pascual T. Villacampa G, et al. JAMA Oncol. 2024 Oct 1;10(10):1331-1341. doi: 10.1001/jamaoncol.2024.3456. JAMA Oncol. 2024. PMID: 39207778 Free PMC article.